- Summits
- Sponsorship
- News
- About
XCath, a medical device company developing robotic technology for neurovascular interventions, has raised $30 million in Series C funding, bringing the company’s total capital raised to $92 million since its founding. The round was co-led by Crescent Enterprises and Dr Fred Moll, Chairman of XCath’s Board of Directors.
The funding will support XCath’s efforts to bring its endovascular robotic platform to market and move toward performing a clinical telerobotic mechanical thrombectomy, an approach that could allow specialists to treat stroke patients remotely.
“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” said Eduardo Fonseca, CEO of XCath. “In 2025 the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”
The financing follows a milestone for the company in November 2025, when its Iris robotic system was used in first-in-human procedures to treat patients with complex brain aneurysms. The procedures were performed by Dr Vitor Mendes Pereira at The Panama Clinic, with Dr Anastasio Ameijeiras Sibauste serving as local principal investigator. The procedures marked only the second time in history that a surgical robot has been used in an intracranial neurovascular intervention.
XCath’s Iris system is currently the only endovascular robotic platform in development to achieve intracranial navigation and neurointerventional treatment. The company noted that the system has also demonstrated the robotic manipulation of three devices during an intracranial procedure and has operated using standard monoplane imaging equipment.
“Robotic surgery succeeds when innovation is paired with practical execution,” said Dr Fred Moll. “XCath has built a promising technology foundation, and just as importantly, a team that values rigour and appreciates perspective. I’m excited to support them as they take on the mission of globalising access to gold-standard care for stroke patients.”
Investor Neeraj Agrawal, who also serves on the XCath board, pointed to the broader investment potential in surgical robotics.
“Surgical robotics represents one of the most compelling long-term investment opportunities in healthcare. XCath has assembled an exceptional team of physicians, entrepreneurs and engineers, clearly focused on addressing a significant global healthcare unmet need,” he said.
According to Nicholas Drysdale, Chief Financial Officer of XCath, stroke and other neurovascular diseases present a substantial opportunity for technological innovation.
“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Drysdale said. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics.”
Founded in 2017, XCath operates from campuses in Houston and Pangyo, developing robotic technologies aimed at improving access to advanced neurovascular procedures worldwide.
Following the success of its Middle East flagship event, MedTech World is now heading to Florida for MedTech World North America, taking place in West Palm Beach from 11 to 13 May 2026.
The North America edition will convene global industry leaders, investors, and innovators for focused discussions, curated networking, and cross-border collaboration opportunities. If you are looking to be part of this milestone flagship event, you can engage in ways that align with your goals:
